###begin article-title 0
Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors
###end article-title 0
###begin title 1
Introduction
###end title 1
###begin p 2
In cancer, an extracellular and membrane bound localization of cathepsins contribute to the invasion of tumor cells at the basement membrane.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 160 161 160 161 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
This is the first study that explored levels of cathepsins B (CatB), L (CatL) and their inhibitor cystatin C (CysC) in the cystic fluid (CF) of ovarian tumors (n = 110).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 312 313 312 313 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 326 327 326 327 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 486 487 486 487 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 595 596 595 596 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 606 607 606 607 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
CF contained considerable amounts of CatB, CatL and CysC. Remarkable differences in CatB and CatL and CysC CF levels were found between different histopathological tumor subtypes. Levels of CatB and CysC were significantly higher in CF of malignant serous tumors compared to those found in benign serous tumors (p = 0.010 and p = 0.001 respectively), whereas levels of CatL were significantly higher in CF of malignant mucinous tumors compared to those found in benign mucinous tumors (p = 0.035). CatB and CysC showed a strong correlation in the group of patients with malignant serous tumors (p < 0.001; R = 0.921) suggesting that the increase in CatB might be balanced by a corresponding increase in CysC.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
Further studies are warranted to investigate cathepsins as possible prognostic biomarkers for the aggressiveness of ovarian cancer.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 284 288 284 288 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2006</xref>
###xml 514 518 514 518 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2008</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Because of the absence of early symptoms, approximately 70% of the patients are diagnosed with FIGO stage III or IV, when tumor cells already have metastasized to the upper abdomen (Colombo et al. 2006). Compared to other types of cancer, insight into the carcinogenesis and progression of ovarian cancer is limited by the lack of a well-defined precursor lesion and by the lack of data from early-stage cancers (Landen et al. 2008).
###end p 11
###begin p 12
###xml 234 238 234 238 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2002</xref>
###xml 247 251 247 251 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">1995</xref>
###xml 270 274 270 274 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2001</xref>
###xml 295 299 295 299 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1993</xref>
###xml 425 429 425 429 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1980</xref>
###xml 443 447 443 447 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2000</xref>
###xml 455 459 455 459 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1996</xref>
###xml 1128 1132 1128 1132 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">2000</xref>
###xml 1145 1149 1145 1149 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2000</xref>
###xml 1165 1169 1165 1169 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2006</xref>
###xml 638 643 <span type="species:ncbi:9606">human</span>
In neoplastic transformation, the epithelial surface first becomes multicell layered. Tumor cells then degrade the basement membrane and invade the stroma or become detached from the primary tumors and metastasize (Capo-Chichi et al. 2002; Scully 1995; Feeley and Wells 2001; Aznavoorian et al. 1993). It is now widely believed that the degradation of the basement membrane is catalyzed by proteolytic enzymes (Liotta et al. 1980; Turk et al. 2000; Duffy 1996). Among these enzymes are the lysosomal cysteine proteinases or cathepsins, which have an important physiological function in regulation of intracellular protein metabolism. The human family of cathepsins has 11 members (cathepsin B, C, F, H, K, L, O, S, V, W and X), which share a conserved active site that is formed by cysteine, histidine and asparagine residues. In cancer tissue, an increased expression of cathepsins has been described and an extracellular and membrane-bound localization of particularly cathepsin B (CatB) and cathepsin L (CatL) has been demonstrated, which might contribute to the invasion of tumor cells at the basement membrane (Turk et al. 2000; Kos et al. 2000; Premzl et al. 2006).
###end p 12
###begin p 13
###xml 101 105 101 105 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1996</xref>
###xml 116 120 116 120 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">1995</xref>
###xml 136 140 136 140 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">1990</xref>
###xml 344 348 344 348 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2000</xref>
###xml 465 469 465 469 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1992</xref>
###xml 482 486 482 486 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1997</xref>
###xml 488 492 488 492 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1998</xref>
###xml 506 511 506 511 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1997a</xref>
###xml 528 532 528 532 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2001</xref>
###xml 546 550 546 550 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2001</xref>
###xml 584 588 584 588 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">1995</xref>
###xml 632 636 632 636 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1995</xref>
###xml 652 656 652 656 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">1997</xref>
###xml 943 947 943 947 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2000</xref>
###xml 962 966 962 966 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1992</xref>
###xml 1212 1216 1212 1216 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1992</xref>
###xml 1405 1409 1405 1409 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1997</xref>
###xml 1428 1432 1428 1432 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 1446 1450 1446 1450 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2001</xref>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 701 709 <span type="species:ncbi:9606">patients</span>
###xml 922 930 <span type="species:ncbi:9606">patients</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
Numerous reports have now been published investigating cancer tissue expression of cathepsins (Duffy 1996; Schwartz 1995; Sloane et al. 1990). Although quantitation of cathepsins in extracellular fluid has several advantages compared to measurement in tissue, reports investigating extracellular cathepsin levels are rather limited (Kos et al. 2000). Higher levels of CatB and CatL were reported in sera of patients with several types of cancer (Gabrijelcic et al. 1992; Kos et al. 1997, 1998; Leto et al. 1997a; Strojan et al. 2001; Zore et al. 2001; Bhuvarahamurthy and Govindasamy 1995), including ovarian cancer (Nishida et al. 1995; Warwas et al. 1997), compared to levels in healthy subjects or patients with benign lesions. The possibility of measuring cathepsins in blood increases its clinical value as a tumor marker, but reported levels in the serum are significantly lower than levels in tumor cells of cancer patients (Kos et al. 2000). Lah et al. (1992) have shown that CatB was present in ascites of patients with ovarian carcinoma. Moreover, they showed that extracellular CatB was inhibited most strongly by cystatin C (CysC), which is an extracellular cysteine proteinase inhibitor (Lah et al. 1992). Recent studies on tissue of breast and ovarian cancer and melanoma showed that an imbalance of CatB/CysC (zonder levels) was correlated with a more aggressive tumor behavior (Kos et al. 1997; Nishikawa et al. 2004; Yano et al. 2001).
###end p 13
###begin p 14
###xml 354 362 <span type="species:ncbi:9606">patients</span>
Most ovarian tumors exhibit, sometimes multiple, cysts that can be large. The cyst fluid (CF) is in close contact with the tumor tissue. To our knowledge, no studies have been performed to investigate the levels of cathepsins or their endogenous inhibitors in this ovarian CF. In the present study, we explored CatB, CatL as well as CysC levels in CF of patients with benign, borderline and malignant ovarian tumors.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and cyst fluid collection
###end title 16
###begin p 17
###xml 498 499 498 499 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 791 803 <span type="species:ncbi:9606">participants</span>
From our biobank containing ovarian cyst fluid (CF) samples of patients with ovarian tumors who underwent primary surgery at the Radboud University Nijmegen Medical Center in the period between 1988 and 1998, small portions of all 110 CF samples were retrieved. Samples in this biobank were collected by aseptic fine needle aspiration at the department of pathology immediately after surgical removal of the tumor. After cooled transport to the laboratory, the CF samples were centrifuged at 3,000xg for 10 min and the supernatant was stored at -35degreesC in small portions until use. Histopathological diagnosis was performed by an experienced gynecologic pathologist and revealed 74 benign, 26 malignant and 10 borderline epithelial ovarian tumors. Informed consent was obtained from all participants.
###end p 17
###begin title 18
ELISA procedures
###end title 18
###begin p 19
###xml 197 201 197 201 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1997</xref>
###xml 367 371 367 371 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">1995</xref>
For the quantitative analysis of CatB, CatL and CysC in ovarian CF, commercially available specific ELISAs (sandwich ELISAs, Krka d.d., Novo mesto, Slovenia) were used, as developed by Kos et al. (1997) at Jozef Stefan Institute, Ljubljana, Slovenia. The components were purified and characterized, and the tests were optimized and performed as described (Kos et al. 1995). To define the optimal dilution, CF samples were serially diluted to the levels encompassing the range of the assays. The linearity of the response was evaluated by comparing the measured values with the calibration curves. The recovery was tested by the addition of different amounts of the antigen to the samples with known antigen concentration that varied from 88 to 108%, comparing expected versus observed concentrations. The intra-assay coefficient of variance varied from 7.6 to 12.7%. CF samples were diluted 1:4 for CatB and CatL and 1:100 for CysC prior to being applied to the wells of microtiter plate. A microplate reader (SLT Rainbow, Salzburg, Austria) was used to measure absorbance. Determination of the levels of cathepsins and CysC was carried out without prior knowledge of the histological or clinical outcome.
###end p 19
###begin title 20
Parameters for aggressiveness of the tumor
###end title 20
###begin p 21
###xml 331 335 331 335 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">1973</xref>
###xml 466 470 466 470 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1999</xref>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
From the pathology and medical reports of the patients with EOC, the following parameters were retrieved: histopathologic subtype and histopathologic grade, age at diagnosis and FIGO stage of disease. Histopathologic subtype and tumor grade were classified according to the World Health Organization (WHO) criteria (Servov et al. (1973)). Staging was performed using the International Federation of Gynaecologists and Obstetricians (FIGO) criteria (Pecorelli et al. 1999). In case of uncertainty about the primary location of the tumor, extensive immunohistochemical staining was performed. Only patients with confirmed primary EOC were included.
###end p 21
###begin title 22
Statistical analyses
###end title 22
###begin p 23
###xml 251 252 251 252 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 471 472 471 472 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Values are shown as median with range (ng/ml). Normality of distributions was analyzed by Kolmogorov-Smirnov testing. Data regarding CatB, CatL and CysC could be normalized by Ln transformation. Differences between two groups were tested by Student's t test, and for more than two groups by ANOVA and subsequent post hoc Tukey's HSD tests. Correlations were assessed by Pearson correlation tests of the Ln-transformed values. A priori significance was set at a two-sided P < 0.05. All statistical analyses were performed using SPSS version 16.0.01 (SPSS Inc. Chicago IL, USA).
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 92 93 90 91 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 167 168 163 164 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 223 224 217 218 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 337 338 331 332 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 358 359 352 353 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 389 390 383 384 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 410 411 404 405 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 509 510 503 504 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 530 531 524 525 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
The mean age at diagnosis was 40 years (SD +/- 14) for patients with benign ovarian tumors (n = 74), 42 years (SD +/- 14) for patients with borderline ovarian tumors (n = 10) and 57 years (SD +/- 11) for patients with EOC (n = 26). The mean age of patients with ovarian cancer was significantly higher than that of patients with benign (p < 0.001, Student's t test) and borderline tumors (p = 0.009, Student's t test). No differences in mean age were found between patients with benign and borderline tumors (p = 0.898, Student's t test).
###end p 25
###begin title 26
Histopathological subtype
###end title 26
###begin p 27
###xml 6 7 6 7 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 311 312 311 312 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 381 382 381 382 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 850 857 850 857 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 949 950 949 950 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 857 995 857 995 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;110) grouped by histopathological subtypes</p>
###xml 857 995 857 995 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;110) grouped by histopathological subtypes</p></caption>
###xml 995 1004 995 1004 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Histology</th>
###xml 1004 1005 1004 1005 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1004 1009 1004 1009 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>N</italic> (%)</th>
###xml 1009 1020 1009 1020 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cathepsin B</th>
###xml 1020 1031 1020 1031 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cathepsin L</th>
###xml 1031 1041 1031 1041 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cystatin C</th>
###xml 995 1041 995 1041 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Histology</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left">Cathepsin L</th><th align="left">Cystatin C</th></tr>
###xml 995 1041 995 1041 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Histology</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left">Cathepsin L</th><th align="left">Cystatin C</th></tr></thead>
###xml 1041 1047 1041 1047 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Benign</td>
###xml 1047 1047 1047 1047 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char"/>
###xml 1047 1047 1047 1047 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1047 1047 1047 1047 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1047 1047 1047 1047 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1041 1047 1041 1047 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Benign</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 1047 1066 1047 1066 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Serous cystadenoma</td>
###xml 1066 1073 1066 1073 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">29 (39)</td>
###xml 1073 1083 1073 1083 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (1&#8211;269)</td>
###xml 1093 1094 1093 1094 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1083 1094 1083 1094 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">31 (9&#8211;121)<sup>a</sup></td>
###xml 1094 1109 1094 1109 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">572 (131&#8211;1,781)</td>
###xml 1047 1109 1047 1109 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (39)</td><td char="(" align="char">12 (1&#8211;269)</td><td char="(" align="char">31 (9&#8211;121)<sup>a</sup></td><td char="(" align="char">572 (131&#8211;1,781)</td></tr>
###xml 1109 1130 1109 1130 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mucinous cystadenoma</td>
###xml 1130 1137 1130 1137 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">21 (28)</td>
###xml 1137 1147 1137 1147 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">16 (1&#8211;227)</td>
###xml 1156 1160 1156 1160 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a, b</sup>
###xml 1147 1160 1147 1160 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (1&#8211;95)<sup>a, b</sup></td>
###xml 1160 1174 1160 1174 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">578 (39&#8211;9,984)</td>
###xml 1109 1174 1109 1174 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (28)</td><td char="(" align="char">16 (1&#8211;227)</td><td char="(" align="char">11 (1&#8211;95)<sup>a, b</sup></td><td char="(" align="char">578 (39&#8211;9,984)</td></tr>
###xml 1174 1187 1174 1187 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Dermoid cyst</td>
###xml 1187 1192 1187 1192 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">5 (7)</td>
###xml 1192 1202 1192 1202 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (1&#8211;108)</td>
###xml 1202 1211 1202 1211 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">10 (2&#8211;97)</td>
###xml 1211 1224 1211 1224 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">618 (117&#8211;876)</td>
###xml 1174 1224 1174 1224 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Dermoid cyst</td><td char="(" align="char">5 (7)</td><td char="(" align="char">11 (1&#8211;108)</td><td char="(" align="char">10 (2&#8211;97)</td><td char="(" align="char">618 (117&#8211;876)</td></tr>
###xml 1224 1245 1224 1245 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Cystic endometriosis</td>
###xml 1245 1252 1245 1252 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">16 (22)</td>
###xml 1252 1262 1252 1262 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">71 (1&#8211;177)</td>
###xml 1272 1273 1272 1273 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1262 1273 1262 1273 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">69 (8&#8211;233)<sup>b</sup></td>
###xml 1273 1287 1273 1287 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">338 (92&#8211;1,931)</td>
###xml 1224 1287 1224 1287 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Cystic endometriosis</td><td char="(" align="char">16 (22)</td><td char="(" align="char">71 (1&#8211;177)</td><td char="(" align="char">69 (8&#8211;233)<sup>b</sup></td><td char="(" align="char">338 (92&#8211;1,931)</td></tr>
###xml 1287 1306 1287 1306 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Corpus luteum cyst</td>
###xml 1306 1311 1306 1311 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">3 (4)</td>
###xml 1311 1320 1311 1320 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">18 (6&#8211;98)</td>
###xml 1320 1331 1320 1331 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">15 (15&#8211;133)</td>
###xml 1331 1346 1331 1346 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">644 (520&#8211;1,805)</td>
###xml 1287 1346 1287 1346 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Corpus luteum cyst</td><td char="(" align="char">3 (4)</td><td char="(" align="char">18 (6&#8211;98)</td><td char="(" align="char">15 (15&#8211;133)</td><td char="(" align="char">644 (520&#8211;1,805)</td></tr>
###xml 1346 1356 1346 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Borderline</td>
###xml 1356 1356 1356 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char"/>
###xml 1356 1356 1356 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1356 1356 1356 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1356 1356 1356 1356 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1346 1356 1346 1356 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Borderline</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 1356 1380 1356 1380 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Serous borderline tumor</td>
###xml 1380 1386 1380 1386 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (20)</td>
###xml 1386 1395 1386 1395 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">14 (8&#8211;21)</td>
###xml 1395 1405 1395 1405 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">28 (18&#8211;38)</td>
###xml 1405 1424 1405 1424 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1,449 (1,125&#8211;1,772)</td>
###xml 1356 1424 1356 1424 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (20)</td><td char="(" align="char">14 (8&#8211;21)</td><td char="(" align="char">28 (18&#8211;38)</td><td char="(" align="char">1,449 (1,125&#8211;1,772)</td></tr>
###xml 1424 1450 1424 1450 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mucinous borderline tumor</td>
###xml 1450 1456 1450 1456 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (60)</td>
###xml 1456 1466 1456 1466 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">31 (2&#8211;118)</td>
###xml 1466 1476 1466 1476 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">75 (8&#8211;166)</td>
###xml 1476 1491 1476 1491 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">697 (474&#8211;3,897)</td>
###xml 1424 1491 1424 1491 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (60)</td><td char="(" align="char">31 (2&#8211;118)</td><td char="(" align="char">75 (8&#8211;166)</td><td char="(" align="char">697 (474&#8211;3,897)</td></tr>
###xml 1491 1520 1491 1520 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mixed-type borderline tumor*</td>
###xml 1520 1526 1520 1526 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (10)</td>
###xml 1526 1529 1526 1529 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">227</td>
###xml 1529 1531 1529 1531 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">92</td>
###xml 1531 1534 1531 1534 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">340</td>
###xml 1491 1534 1491 1534 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mixed-type borderline tumor*</td><td char="(" align="char">1 (10)</td><td char="(" align="char">227</td><td char="(" align="char">92</td><td char="(" align="char">340</td></tr>
###xml 1534 1542 1534 1542 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Unknown</td>
###xml 1542 1548 1542 1548 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (10)</td>
###xml 1548 1548 1548 1548 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1548 1548 1548 1548 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1548 1548 1548 1548 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1534 1548 1534 1548 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Unknown</td><td char="(" align="char">1 (10)</td><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 1548 1557 1548 1557 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Malignant</td>
###xml 1557 1557 1557 1557 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char"/>
###xml 1557 1557 1557 1557 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1557 1557 1557 1557 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1557 1557 1557 1557 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1548 1557 1548 1557 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Malignant</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 1557 1583 1557 1583 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Serous cystadenocarcinoma</td>
###xml 1583 1590 1583 1590 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">10 (38)</td>
###xml 1590 1600 1590 1600 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">65 (3&#8211;269)</td>
###xml 1600 1610 1600 1610 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">61 (8&#8211;163)</td>
###xml 1610 1627 1610 1627 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1,443 (448&#8211;5,972)</td>
###xml 1557 1627 1557 1627 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (38)</td><td char="(" align="char">65 (3&#8211;269)</td><td char="(" align="char">61 (8&#8211;163)</td><td char="(" align="char">1,443 (448&#8211;5,972)</td></tr>
###xml 1627 1655 1627 1655 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mucinous cystadenocarcinoma</td>
###xml 1655 1661 1655 1661 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">8 (31)</td>
###xml 1661 1671 1661 1671 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">33 (5&#8211;269)</td>
###xml 1671 1682 1671 1682 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">31 (13&#8211;187)</td>
###xml 1682 1697 1682 1697 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">959 (399&#8211;9,984)</td>
###xml 1627 1697 1627 1697 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (31)</td><td char="(" align="char">33 (5&#8211;269)</td><td char="(" align="char">31 (13&#8211;187)</td><td char="(" align="char">959 (399&#8211;9,984)</td></tr>
###xml 1697 1729 1697 1729 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Endometrioid cystadenocarcinoma</td>
###xml 1729 1735 1729 1735 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (23)</td>
###xml 1735 1745 1735 1745 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">85 (1&#8211;269)</td>
###xml 1745 1756 1745 1756 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">71 (14&#8211;181)</td>
###xml 1756 1772 1756 1772 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1,200 (64&#8211;2,907)</td>
###xml 1697 1772 1697 1772 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Endometrioid cystadenocarcinoma</td><td char="(" align="char">6 (23)</td><td char="(" align="char">85 (1&#8211;269)</td><td char="(" align="char">71 (14&#8211;181)</td><td char="(" align="char">1,200 (64&#8211;2,907)</td></tr>
###xml 1772 1803 1772 1803 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mixed-type cystadenocarcinoma*</td>
###xml 1803 1808 1803 1808 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (4)</td>
###xml 1808 1810 1808 1810 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">95</td>
###xml 1810 1812 1810 1812 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">67</td>
###xml 1812 1817 1812 1817 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1,232</td>
###xml 1772 1817 1772 1817 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mixed-type cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">95</td><td char="(" align="char">67</td><td char="(" align="char">1,232</td></tr>
###xml 1817 1854 1817 1854 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Undifferentiated cystadenocarcinoma*</td>
###xml 1854 1859 1854 1859 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1 (4)</td>
###xml 1859 1862 1859 1862 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">110</td>
###xml 1862 1864 1862 1864 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">75</td>
###xml 1864 1867 1864 1867 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">109</td>
###xml 1817 1867 1817 1867 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Undifferentiated cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">110</td><td char="(" align="char">75</td><td char="(" align="char">109</td></tr>
###xml 1041 1867 1041 1867 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Benign</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (39)</td><td char="(" align="char">12 (1&#8211;269)</td><td char="(" align="char">31 (9&#8211;121)<sup>a</sup></td><td char="(" align="char">572 (131&#8211;1,781)</td></tr><tr><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (28)</td><td char="(" align="char">16 (1&#8211;227)</td><td char="(" align="char">11 (1&#8211;95)<sup>a, b</sup></td><td char="(" align="char">578 (39&#8211;9,984)</td></tr><tr><td align="left">&#160;Dermoid cyst</td><td char="(" align="char">5 (7)</td><td char="(" align="char">11 (1&#8211;108)</td><td char="(" align="char">10 (2&#8211;97)</td><td char="(" align="char">618 (117&#8211;876)</td></tr><tr><td align="left">&#160;Cystic endometriosis</td><td char="(" align="char">16 (22)</td><td char="(" align="char">71 (1&#8211;177)</td><td char="(" align="char">69 (8&#8211;233)<sup>b</sup></td><td char="(" align="char">338 (92&#8211;1,931)</td></tr><tr><td align="left">&#160;Corpus luteum cyst</td><td char="(" align="char">3 (4)</td><td char="(" align="char">18 (6&#8211;98)</td><td char="(" align="char">15 (15&#8211;133)</td><td char="(" align="char">644 (520&#8211;1,805)</td></tr><tr><td align="left">Borderline</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (20)</td><td char="(" align="char">14 (8&#8211;21)</td><td char="(" align="char">28 (18&#8211;38)</td><td char="(" align="char">1,449 (1,125&#8211;1,772)</td></tr><tr><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (60)</td><td char="(" align="char">31 (2&#8211;118)</td><td char="(" align="char">75 (8&#8211;166)</td><td char="(" align="char">697 (474&#8211;3,897)</td></tr><tr><td align="left">&#160;Mixed-type borderline tumor*</td><td char="(" align="char">1 (10)</td><td char="(" align="char">227</td><td char="(" align="char">92</td><td char="(" align="char">340</td></tr><tr><td align="left">&#160;Unknown</td><td char="(" align="char">1 (10)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Malignant</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (38)</td><td char="(" align="char">65 (3&#8211;269)</td><td char="(" align="char">61 (8&#8211;163)</td><td char="(" align="char">1,443 (448&#8211;5,972)</td></tr><tr><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (31)</td><td char="(" align="char">33 (5&#8211;269)</td><td char="(" align="char">31 (13&#8211;187)</td><td char="(" align="char">959 (399&#8211;9,984)</td></tr><tr><td align="left">&#160;Endometrioid cystadenocarcinoma</td><td char="(" align="char">6 (23)</td><td char="(" align="char">85 (1&#8211;269)</td><td char="(" align="char">71 (14&#8211;181)</td><td char="(" align="char">1,200 (64&#8211;2,907)</td></tr><tr><td align="left">&#160;Mixed-type cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">95</td><td char="(" align="char">67</td><td char="(" align="char">1,232</td></tr><tr><td align="left">&#160;Undifferentiated cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">110</td><td char="(" align="char">75</td><td char="(" align="char">109</td></tr></tbody>
###xml 995 1867 995 1867 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Histology</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left">Cathepsin L</th><th align="left">Cystatin C</th></tr></thead><tbody><tr><td align="left">Benign</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (39)</td><td char="(" align="char">12 (1&#8211;269)</td><td char="(" align="char">31 (9&#8211;121)<sup>a</sup></td><td char="(" align="char">572 (131&#8211;1,781)</td></tr><tr><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (28)</td><td char="(" align="char">16 (1&#8211;227)</td><td char="(" align="char">11 (1&#8211;95)<sup>a, b</sup></td><td char="(" align="char">578 (39&#8211;9,984)</td></tr><tr><td align="left">&#160;Dermoid cyst</td><td char="(" align="char">5 (7)</td><td char="(" align="char">11 (1&#8211;108)</td><td char="(" align="char">10 (2&#8211;97)</td><td char="(" align="char">618 (117&#8211;876)</td></tr><tr><td align="left">&#160;Cystic endometriosis</td><td char="(" align="char">16 (22)</td><td char="(" align="char">71 (1&#8211;177)</td><td char="(" align="char">69 (8&#8211;233)<sup>b</sup></td><td char="(" align="char">338 (92&#8211;1,931)</td></tr><tr><td align="left">&#160;Corpus luteum cyst</td><td char="(" align="char">3 (4)</td><td char="(" align="char">18 (6&#8211;98)</td><td char="(" align="char">15 (15&#8211;133)</td><td char="(" align="char">644 (520&#8211;1,805)</td></tr><tr><td align="left">Borderline</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (20)</td><td char="(" align="char">14 (8&#8211;21)</td><td char="(" align="char">28 (18&#8211;38)</td><td char="(" align="char">1,449 (1,125&#8211;1,772)</td></tr><tr><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (60)</td><td char="(" align="char">31 (2&#8211;118)</td><td char="(" align="char">75 (8&#8211;166)</td><td char="(" align="char">697 (474&#8211;3,897)</td></tr><tr><td align="left">&#160;Mixed-type borderline tumor*</td><td char="(" align="char">1 (10)</td><td char="(" align="char">227</td><td char="(" align="char">92</td><td char="(" align="char">340</td></tr><tr><td align="left">&#160;Unknown</td><td char="(" align="char">1 (10)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Malignant</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (38)</td><td char="(" align="char">65 (3&#8211;269)</td><td char="(" align="char">61 (8&#8211;163)</td><td char="(" align="char">1,443 (448&#8211;5,972)</td></tr><tr><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (31)</td><td char="(" align="char">33 (5&#8211;269)</td><td char="(" align="char">31 (13&#8211;187)</td><td char="(" align="char">959 (399&#8211;9,984)</td></tr><tr><td align="left">&#160;Endometrioid cystadenocarcinoma</td><td char="(" align="char">6 (23)</td><td char="(" align="char">85 (1&#8211;269)</td><td char="(" align="char">71 (14&#8211;181)</td><td char="(" align="char">1,200 (64&#8211;2,907)</td></tr><tr><td align="left">&#160;Mixed-type cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">95</td><td char="(" align="char">67</td><td char="(" align="char">1,232</td></tr><tr><td align="left">&#160;Undifferentiated cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">110</td><td char="(" align="char">75</td><td char="(" align="char">109</td></tr></tbody></table>
###xml 1867 1868 1867 1868 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1947 1948 1947 1948 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1867 2033 1867 2033 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><sup>*</sup>A single concentration is listed. Statistical significance according to ANOVA (<italic>p</italic>&#160;=&#160;0.001) with Tukey&#8217;s HSD post hoc test of values normalized after Ln transformation</p>
###xml 2033 2034 2033 2034 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2034 2035 2034 2035 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2033 2101 2033 2101 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="30"><sup>a</sup><italic>p</italic>&#160;=&#160;0.003 for mucinous cystadenomas compared to serous cystadenomas</p>
###xml 2101 2102 2101 2102 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2102 2103 2102 2103 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2101 2170 2101 2170 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><sup>b</sup><italic>p</italic>&#160;&lt;&#160;0.001 for mucinous cystadenomas compared to cystic endometriosis</p>
###xml 1867 2170 1867 2170 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><sup>*</sup>A single concentration is listed. Statistical significance according to ANOVA (<italic>p</italic>&#160;=&#160;0.001) with Tukey&#8217;s HSD post hoc test of values normalized after Ln transformation</p><p textid="30"><sup>a</sup><italic>p</italic>&#160;=&#160;0.003 for mucinous cystadenomas compared to serous cystadenomas</p><p textid="31"><sup>b</sup><italic>p</italic>&#160;&lt;&#160;0.001 for mucinous cystadenomas compared to cystic endometriosis</p></table-wrap-foot>
###xml 850 2170 850 2170 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="28">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;110) grouped by histopathological subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Histology</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left">Cathepsin L</th><th align="left">Cystatin C</th></tr></thead><tbody><tr><td align="left">Benign</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (39)</td><td char="(" align="char">12 (1&#8211;269)</td><td char="(" align="char">31 (9&#8211;121)<sup>a</sup></td><td char="(" align="char">572 (131&#8211;1,781)</td></tr><tr><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (28)</td><td char="(" align="char">16 (1&#8211;227)</td><td char="(" align="char">11 (1&#8211;95)<sup>a, b</sup></td><td char="(" align="char">578 (39&#8211;9,984)</td></tr><tr><td align="left">&#160;Dermoid cyst</td><td char="(" align="char">5 (7)</td><td char="(" align="char">11 (1&#8211;108)</td><td char="(" align="char">10 (2&#8211;97)</td><td char="(" align="char">618 (117&#8211;876)</td></tr><tr><td align="left">&#160;Cystic endometriosis</td><td char="(" align="char">16 (22)</td><td char="(" align="char">71 (1&#8211;177)</td><td char="(" align="char">69 (8&#8211;233)<sup>b</sup></td><td char="(" align="char">338 (92&#8211;1,931)</td></tr><tr><td align="left">&#160;Corpus luteum cyst</td><td char="(" align="char">3 (4)</td><td char="(" align="char">18 (6&#8211;98)</td><td char="(" align="char">15 (15&#8211;133)</td><td char="(" align="char">644 (520&#8211;1,805)</td></tr><tr><td align="left">Borderline</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (20)</td><td char="(" align="char">14 (8&#8211;21)</td><td char="(" align="char">28 (18&#8211;38)</td><td char="(" align="char">1,449 (1,125&#8211;1,772)</td></tr><tr><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (60)</td><td char="(" align="char">31 (2&#8211;118)</td><td char="(" align="char">75 (8&#8211;166)</td><td char="(" align="char">697 (474&#8211;3,897)</td></tr><tr><td align="left">&#160;Mixed-type borderline tumor*</td><td char="(" align="char">1 (10)</td><td char="(" align="char">227</td><td char="(" align="char">92</td><td char="(" align="char">340</td></tr><tr><td align="left">&#160;Unknown</td><td char="(" align="char">1 (10)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Malignant</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (38)</td><td char="(" align="char">65 (3&#8211;269)</td><td char="(" align="char">61 (8&#8211;163)</td><td char="(" align="char">1,443 (448&#8211;5,972)</td></tr><tr><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (31)</td><td char="(" align="char">33 (5&#8211;269)</td><td char="(" align="char">31 (13&#8211;187)</td><td char="(" align="char">959 (399&#8211;9,984)</td></tr><tr><td align="left">&#160;Endometrioid cystadenocarcinoma</td><td char="(" align="char">6 (23)</td><td char="(" align="char">85 (1&#8211;269)</td><td char="(" align="char">71 (14&#8211;181)</td><td char="(" align="char">1,200 (64&#8211;2,907)</td></tr><tr><td align="left">&#160;Mixed-type cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">95</td><td char="(" align="char">67</td><td char="(" align="char">1,232</td></tr><tr><td align="left">&#160;Undifferentiated cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">110</td><td char="(" align="char">75</td><td char="(" align="char">109</td></tr></tbody></table><table-wrap-foot><p textid="29"><sup>*</sup>A single concentration is listed. Statistical significance according to ANOVA (<italic>p</italic>&#160;=&#160;0.001) with Tukey&#8217;s HSD post hoc test of values normalized after Ln transformation</p><p textid="30"><sup>a</sup><italic>p</italic>&#160;=&#160;0.003 for mucinous cystadenomas compared to serous cystadenomas</p><p textid="31"><sup>b</sup><italic>p</italic>&#160;&lt;&#160;0.001 for mucinous cystadenomas compared to cystic endometriosis</p></table-wrap-foot></table-wrap>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Table 1 shows the median (range) concentrations of CatB, CatL and CysC in ovarian CF of patients with malignant, borderline and benign ovarian tumors, grouped by histological subtype. Within the benign group, CF levels of CatL were significantly different between serous cystadenomas and mucinous cystadenomas (p = 0.003) and between endometriosis cysts and mucinous cystadenomas (p < 0.001). Although generally not significantly different from the other benign histological subtypes, the median concentrations of CatB and CatL in cystic endometriosis were remarkably high and comparable to those found in CF of malignant tumors. CysC concentrations were in the same range for all benign subclasses. Within the group of borderline and malignant tumors, CF levels of CatB, CatL and CysC did not differ significantly between histopathological subtypes.Table 1Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (n = 110) grouped by histopathological subtypesHistologyN (%)Cathepsin BCathepsin LCystatin CBenign Serous cystadenoma29 (39)12 (1-269)31 (9-121)a572 (131-1,781) Mucinous cystadenoma21 (28)16 (1-227)11 (1-95)a, b578 (39-9,984) Dermoid cyst5 (7)11 (1-108)10 (2-97)618 (117-876) Cystic endometriosis16 (22)71 (1-177)69 (8-233)b338 (92-1,931) Corpus luteum cyst3 (4)18 (6-98)15 (15-133)644 (520-1,805)Borderline Serous borderline tumor2 (20)14 (8-21)28 (18-38)1,449 (1,125-1,772) Mucinous borderline tumor6 (60)31 (2-118)75 (8-166)697 (474-3,897) Mixed-type borderline tumor*1 (10)22792340 Unknown1 (10)Malignant Serous cystadenocarcinoma10 (38)65 (3-269)61 (8-163)1,443 (448-5,972) Mucinous cystadenocarcinoma8 (31)33 (5-269)31 (13-187)959 (399-9,984) Endometrioid cystadenocarcinoma6 (23)85 (1-269)71 (14-181)1,200 (64-2,907) Mixed-type cystadenocarcinoma*1 (4)95671,232 Undifferentiated cystadenocarcinoma*1 (4)11075109*A single concentration is listed. Statistical significance according to ANOVA (p = 0.001) with Tukey's HSD post hoc test of values normalized after Ln transformationap = 0.003 for mucinous cystadenomas compared to serous cystadenomasbp < 0.001 for mucinous cystadenomas compared to cystic endometriosis
###end p 27
###begin p 28
###xml 92 93 92 93 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (n = 110) grouped by histopathological subtypes
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 80 81 80 81 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
*A single concentration is listed. Statistical significance according to ANOVA (p = 0.001) with Tukey's HSD post hoc test of values normalized after Ln transformation
###end p 29
###begin p 30
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
ap = 0.003 for mucinous cystadenomas compared to serous cystadenomas
###end p 30
###begin p 31
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1 2 1 2 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
bp < 0.001 for mucinous cystadenomas compared to cystic endometriosis
###end p 31
###begin p 32
###xml 6 7 6 7 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 17 18 17 18 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 220 221 220 221 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 349 350 349 350 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 478 479 478 479 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 607 608 607 608 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 805 806 805 806 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 816 823 816 823 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 915 916 915 916 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 823 1004 823 1004 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;67) of benign, borderline and malignant tumors grouped by serous and mucinous subtype</p>
###xml 823 1004 823 1004 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;67) of benign, borderline and malignant tumors grouped by serous and mucinous subtype</p></caption>
###xml 1004 1011 1004 1011 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Subtype</th>
###xml 1011 1012 1011 1012 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1011 1016 1011 1016 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>N</italic> (%)</th>
###xml 1016 1027 1016 1027 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cathepsin B</th>
###xml 1027 1028 1027 1028 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1034 1035 1034 1035 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1027 1035 1027 1035 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic>-value<sup>*</sup></th>
###xml 1035 1046 1035 1046 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cathepsin L</th>
###xml 1046 1047 1046 1047 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1053 1054 1053 1054 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1046 1054 1046 1054 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic>-value<sup>*</sup></th>
###xml 1054 1064 1054 1064 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cystatin C</th>
###xml 1064 1065 1064 1065 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1071 1072 1071 1072 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1064 1072 1064 1072 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic>-value<sup>*</sup></th>
###xml 1004 1072 1004 1072 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Subtype</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value<sup>*</sup></th></tr>
###xml 1004 1072 1004 1072 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Subtype</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value<sup>*</sup></th></tr></thead>
###xml 1072 1078 1072 1078 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Serous</td>
###xml 1078 1080 1078 1080 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">41</td>
###xml 1080 1080 1080 1080 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1080 1085 1080 1085 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.031</italic>
###xml 1080 1085 1080 1085 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><italic>0.031</italic></td>
###xml 1085 1085 1085 1085 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1085 1090 1085 1090 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.131</td>
###xml 1090 1090 1090 1090 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1090 1095 1090 1095 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.001</italic>
###xml 1090 1095 1090 1095 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"><italic>0.001</italic></td>
###xml 1072 1095 1072 1095 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Serous</td><td char="(" align="char">41</td><td align="left"/><td char="." align="char"><italic>0.031</italic></td><td align="left"/><td align="left">0.131</td><td align="left"/><td char="." align="char"><italic>0.001</italic></td></tr>
###xml 1095 1114 1095 1114 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Serous cystadenoma</td>
###xml 1114 1121 1114 1121 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">29 (71)</td>
###xml 1131 1132 1131 1132 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1121 1132 1121 1132 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (1&#8211;269)<sup>a</sup></td>
###xml 1132 1132 1132 1132 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1132 1142 1132 1142 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">31 (9&#8211;121)</td>
###xml 1142 1142 1142 1142 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1157 1158 1157 1158 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1142 1158 1142 1158 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">572 (131&#8211;1,780)<sup>b</sup></td>
###xml 1158 1158 1158 1158 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1095 1158 1095 1158 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (71)</td><td char="(" align="char">12 (1&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">31 (9&#8211;121)</td><td align="left"/><td char="(" align="char">572 (131&#8211;1,780)<sup>b</sup></td><td align="left"/></tr>
###xml 1158 1182 1158 1182 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Serous borderline tumor</td>
###xml 1182 1187 1182 1187 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">2 (5)</td>
###xml 1187 1196 1187 1196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">14 (8&#8211;21)</td>
###xml 1196 1196 1196 1196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1196 1206 1196 1206 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">28 (18&#8211;38)</td>
###xml 1206 1206 1206 1206 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1206 1225 1206 1225 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1,449 (1,125&#8211;1,772)</td>
###xml 1225 1225 1225 1225 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1158 1225 1158 1225 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (5)</td><td char="(" align="char">14 (8&#8211;21)</td><td align="left"/><td char="(" align="char">28 (18&#8211;38)</td><td align="left"/><td char="(" align="char">1,449 (1,125&#8211;1,772)</td><td align="left"/></tr>
###xml 1225 1251 1225 1251 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Serous cystadenocarcinoma</td>
###xml 1251 1258 1251 1258 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">10 (24)</td>
###xml 1268 1269 1268 1269 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1258 1269 1258 1269 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">65 (3&#8211;269)<sup>a</sup></td>
###xml 1269 1269 1269 1269 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1269 1279 1269 1279 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">61 (8&#8211;163)</td>
###xml 1279 1279 1279 1279 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1296 1297 1296 1297 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1279 1297 1279 1297 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">1,443 (448&#8211;5,972)<sup>b</sup></td>
###xml 1297 1297 1297 1297 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1225 1297 1225 1297 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (24)</td><td char="(" align="char">65 (3&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">61 (8&#8211;163)</td><td align="left"/><td char="(" align="char">1,443 (448&#8211;5,972)<sup>b</sup></td><td align="left"/></tr>
###xml 1297 1305 1297 1305 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mucinous</td>
###xml 1305 1307 1305 1307 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">35</td>
###xml 1307 1307 1307 1307 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1307 1312 1307 1312 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.315</td>
###xml 1312 1312 1312 1312 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1312 1317 1312 1317 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.017</italic>
###xml 1312 1317 1312 1317 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>0.017</italic></td>
###xml 1317 1317 1317 1317 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1317 1322 1317 1322 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.136</td>
###xml 1297 1322 1297 1322 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Mucinous</td><td char="(" align="char">35</td><td align="left"/><td char="." align="char">0.315</td><td align="left"/><td align="left"><italic>0.017</italic></td><td align="left"/><td char="." align="char">0.136</td></tr>
###xml 1322 1343 1322 1343 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mucinous cystadenoma</td>
###xml 1343 1350 1343 1350 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">21 (60)</td>
###xml 1350 1360 1350 1360 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">16 (1&#8211;227)</td>
###xml 1360 1360 1360 1360 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1369 1370 1369 1370 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1360 1370 1360 1370 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">11 (1&#8211;95)<sup>c</sup></td>
###xml 1370 1370 1370 1370 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1370 1384 1370 1384 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">578 (39&#8211;9,984)</td>
###xml 1384 1384 1384 1384 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1322 1384 1322 1384 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (60)</td><td char="(" align="char">16 (1&#8211;227)</td><td align="left"/><td char="(" align="char">11 (1&#8211;95)<sup>c</sup></td><td align="left"/><td char="(" align="char">578 (39&#8211;9,984)</td><td align="left"/></tr>
###xml 1384 1410 1384 1410 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mucinous borderline tumor</td>
###xml 1410 1416 1410 1416 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">6 (17)</td>
###xml 1416 1426 1416 1426 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">32 (2&#8211;118)</td>
###xml 1426 1426 1426 1426 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1426 1436 1426 1436 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">75 (8&#8211;166)</td>
###xml 1436 1436 1436 1436 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1436 1451 1436 1451 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">697 (474&#8211;3,897)</td>
###xml 1451 1451 1451 1451 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1384 1451 1384 1451 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (17)</td><td char="(" align="char">32 (2&#8211;118)</td><td align="left"/><td char="(" align="char">75 (8&#8211;166)</td><td align="left"/><td char="(" align="char">697 (474&#8211;3,897)</td><td align="left"/></tr>
###xml 1451 1479 1451 1479 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Mucinous cystadenocarcinoma</td>
###xml 1479 1485 1479 1485 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">8 (23)</td>
###xml 1485 1495 1485 1495 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">33 (5&#8211;269)</td>
###xml 1495 1495 1495 1495 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1506 1507 1506 1507 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1495 1507 1495 1507 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">31 (13&#8211;187)<sup>c</sup></td>
###xml 1507 1507 1507 1507 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1507 1522 1507 1522 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">959 (399&#8211;9,984)</td>
###xml 1522 1522 1522 1522 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1451 1522 1451 1522 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (23)</td><td char="(" align="char">33 (5&#8211;269)</td><td align="left"/><td char="(" align="char">31 (13&#8211;187)<sup>c</sup></td><td align="left"/><td char="(" align="char">959 (399&#8211;9,984)</td><td align="left"/></tr>
###xml 1072 1522 1072 1522 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Serous</td><td char="(" align="char">41</td><td align="left"/><td char="." align="char"><italic>0.031</italic></td><td align="left"/><td align="left">0.131</td><td align="left"/><td char="." align="char"><italic>0.001</italic></td></tr><tr><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (71)</td><td char="(" align="char">12 (1&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">31 (9&#8211;121)</td><td align="left"/><td char="(" align="char">572 (131&#8211;1,780)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (5)</td><td char="(" align="char">14 (8&#8211;21)</td><td align="left"/><td char="(" align="char">28 (18&#8211;38)</td><td align="left"/><td char="(" align="char">1,449 (1,125&#8211;1,772)</td><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (24)</td><td char="(" align="char">65 (3&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">61 (8&#8211;163)</td><td align="left"/><td char="(" align="char">1,443 (448&#8211;5,972)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">Mucinous</td><td char="(" align="char">35</td><td align="left"/><td char="." align="char">0.315</td><td align="left"/><td align="left"><italic>0.017</italic></td><td align="left"/><td char="." align="char">0.136</td></tr><tr><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (60)</td><td char="(" align="char">16 (1&#8211;227)</td><td align="left"/><td char="(" align="char">11 (1&#8211;95)<sup>c</sup></td><td align="left"/><td char="(" align="char">578 (39&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (17)</td><td char="(" align="char">32 (2&#8211;118)</td><td align="left"/><td char="(" align="char">75 (8&#8211;166)</td><td align="left"/><td char="(" align="char">697 (474&#8211;3,897)</td><td align="left"/></tr><tr><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (23)</td><td char="(" align="char">33 (5&#8211;269)</td><td align="left"/><td char="(" align="char">31 (13&#8211;187)<sup>c</sup></td><td align="left"/><td char="(" align="char">959 (399&#8211;9,984)</td><td align="left"/></tr></tbody>
###xml 1004 1522 1004 1522 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Subtype</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td align="left">Serous</td><td char="(" align="char">41</td><td align="left"/><td char="." align="char"><italic>0.031</italic></td><td align="left"/><td align="left">0.131</td><td align="left"/><td char="." align="char"><italic>0.001</italic></td></tr><tr><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (71)</td><td char="(" align="char">12 (1&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">31 (9&#8211;121)</td><td align="left"/><td char="(" align="char">572 (131&#8211;1,780)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (5)</td><td char="(" align="char">14 (8&#8211;21)</td><td align="left"/><td char="(" align="char">28 (18&#8211;38)</td><td align="left"/><td char="(" align="char">1,449 (1,125&#8211;1,772)</td><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (24)</td><td char="(" align="char">65 (3&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">61 (8&#8211;163)</td><td align="left"/><td char="(" align="char">1,443 (448&#8211;5,972)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">Mucinous</td><td char="(" align="char">35</td><td align="left"/><td char="." align="char">0.315</td><td align="left"/><td align="left"><italic>0.017</italic></td><td align="left"/><td char="." align="char">0.136</td></tr><tr><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (60)</td><td char="(" align="char">16 (1&#8211;227)</td><td align="left"/><td char="(" align="char">11 (1&#8211;95)<sup>c</sup></td><td align="left"/><td char="(" align="char">578 (39&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (17)</td><td char="(" align="char">32 (2&#8211;118)</td><td align="left"/><td char="(" align="char">75 (8&#8211;166)</td><td align="left"/><td char="(" align="char">697 (474&#8211;3,897)</td><td align="left"/></tr><tr><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (23)</td><td char="(" align="char">33 (5&#8211;269)</td><td align="left"/><td char="(" align="char">31 (13&#8211;187)<sup>c</sup></td><td align="left"/><td char="(" align="char">959 (399&#8211;9,984)</td><td align="left"/></tr></tbody></table>
###xml 1522 1523 1522 1523 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1522 1566 1522 1566 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><sup>*</sup>Statistical significance according to ANOVA</p>
###xml 1576 1577 1576 1577 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1582 1589 1582 1589 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a, b, c</sup>
###xml 1566 1634 1566 1634 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Student&#8217;s <italic>t</italic> test<sup>a, b, c</sup> of values normalized after Ln transformation</p>
###xml 1634 1635 1634 1635 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1635 1636 1635 1636 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1634 1705 1634 1705 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><sup>a</sup><italic>p</italic>&#160;=&#160;0.010 for serous cystadenoma compared to serous cystadenocarcinoma</p>
###xml 1705 1706 1705 1706 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1706 1707 1706 1707 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1705 1776 1705 1776 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><sup>b</sup><italic>p</italic>&#160;=&#160;0.001 for serous cystadenoma compared to serous cystadenocarcinoma</p>
###xml 1776 1777 1776 1777 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1777 1778 1777 1778 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1776 1851 1776 1851 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><sup>c</sup><italic>p</italic>&#160;=&#160;0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinoma</p>
###xml 1522 1851 1522 1851 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34"><sup>*</sup>Statistical significance according to ANOVA</p><p textid="35">Student&#8217;s <italic>t</italic> test<sup>a, b, c</sup> of values normalized after Ln transformation</p><p textid="36"><sup>a</sup><italic>p</italic>&#160;=&#160;0.010 for serous cystadenoma compared to serous cystadenocarcinoma</p><p textid="37"><sup>b</sup><italic>p</italic>&#160;=&#160;0.001 for serous cystadenoma compared to serous cystadenocarcinoma</p><p textid="38"><sup>c</sup><italic>p</italic>&#160;=&#160;0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinoma</p></table-wrap-foot>
###xml 816 1851 816 1851 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="33">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;67) of benign, borderline and malignant tumors grouped by serous and mucinous subtype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Subtype</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td align="left">Serous</td><td char="(" align="char">41</td><td align="left"/><td char="." align="char"><italic>0.031</italic></td><td align="left"/><td align="left">0.131</td><td align="left"/><td char="." align="char"><italic>0.001</italic></td></tr><tr><td align="left">&#160;Serous cystadenoma</td><td char="(" align="char">29 (71)</td><td char="(" align="char">12 (1&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">31 (9&#8211;121)</td><td align="left"/><td char="(" align="char">572 (131&#8211;1,780)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">&#160;Serous borderline tumor</td><td char="(" align="char">2 (5)</td><td char="(" align="char">14 (8&#8211;21)</td><td align="left"/><td char="(" align="char">28 (18&#8211;38)</td><td align="left"/><td char="(" align="char">1,449 (1,125&#8211;1,772)</td><td align="left"/></tr><tr><td align="left">&#160;Serous cystadenocarcinoma</td><td char="(" align="char">10 (24)</td><td char="(" align="char">65 (3&#8211;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">61 (8&#8211;163)</td><td align="left"/><td char="(" align="char">1,443 (448&#8211;5,972)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">Mucinous</td><td char="(" align="char">35</td><td align="left"/><td char="." align="char">0.315</td><td align="left"/><td align="left"><italic>0.017</italic></td><td align="left"/><td char="." align="char">0.136</td></tr><tr><td align="left">&#160;Mucinous cystadenoma</td><td char="(" align="char">21 (60)</td><td char="(" align="char">16 (1&#8211;227)</td><td align="left"/><td char="(" align="char">11 (1&#8211;95)<sup>c</sup></td><td align="left"/><td char="(" align="char">578 (39&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;Mucinous borderline tumor</td><td char="(" align="char">6 (17)</td><td char="(" align="char">32 (2&#8211;118)</td><td align="left"/><td char="(" align="char">75 (8&#8211;166)</td><td align="left"/><td char="(" align="char">697 (474&#8211;3,897)</td><td align="left"/></tr><tr><td align="left">&#160;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (23)</td><td char="(" align="char">33 (5&#8211;269)</td><td align="left"/><td char="(" align="char">31 (13&#8211;187)<sup>c</sup></td><td align="left"/><td char="(" align="char">959 (399&#8211;9,984)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p textid="34"><sup>*</sup>Statistical significance according to ANOVA</p><p textid="35">Student&#8217;s <italic>t</italic> test<sup>a, b, c</sup> of values normalized after Ln transformation</p><p textid="36"><sup>a</sup><italic>p</italic>&#160;=&#160;0.010 for serous cystadenoma compared to serous cystadenocarcinoma</p><p textid="37"><sup>b</sup><italic>p</italic>&#160;=&#160;0.001 for serous cystadenoma compared to serous cystadenocarcinoma</p><p textid="38"><sup>c</sup><italic>p</italic>&#160;=&#160;0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinoma</p></table-wrap-foot></table-wrap>
###xml 1851 1857 1851 1857 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1875 1876 1875 1876 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1895 1896 1895 1896 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1916 1917 1916 1917 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2196 2197 2196 2197 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1857 2282 1857 2282 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Box plots of the (<bold>a</bold>) cathepsin B and (<bold>b</bold>) cathepsin L, and (<bold>c</bold>) cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst fluid for patients with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors). Statistical significance above the subfigures are according to ANOVA (<italic>P</italic>&#160;&lt;&#160;0.05) with Tukey&#8217;s HSD post hoc tests of values normalized after Ln transformation</p>
###xml 1857 2282 1857 2282 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Box plots of the (<bold>a</bold>) cathepsin B and (<bold>b</bold>) cathepsin L, and (<bold>c</bold>) cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst fluid for patients with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors). Statistical significance above the subfigures are according to ANOVA (<italic>P</italic>&#160;&lt;&#160;0.05) with Tukey&#8217;s HSD post hoc tests of values normalized after Ln transformation</p></caption>
###xml 2282 2282 2282 2282 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="432_2009_716_Fig1_HTML" id="MO1"/>
###xml 1851 2282 1851 2282 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="39">Box plots of the (<bold>a</bold>) cathepsin B and (<bold>b</bold>) cathepsin L, and (<bold>c</bold>) cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst fluid for patients with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors). Statistical significance above the subfigures are according to ANOVA (<italic>P</italic>&#160;&lt;&#160;0.05) with Tukey&#8217;s HSD post hoc tests of values normalized after Ln transformation</p></caption><graphic xlink:href="432_2009_716_Fig1_HTML" id="MO1"/></fig>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 535 543 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
###xml 1999 2007 <span type="species:ncbi:9606">patients</span>
Table 2 and Fig. 1 show median (range) CF levels of CatB, CatL and CysC in benign (cystadenoma), borderline and malignant (cystadenocarcinoma) ovarian tumors according to the histopathological subtype. In serous tumors (n = 41), CF levels of CatB were significantly higher for patients with malignant tumors compared to patients with benign tumors (p = 0.010), whereas CatL levels did not differ significantly within this histological subgroup. In contrast, in mucinous tumors (n = 35), CF levels of CatL were significantly higher for patients with malignant tumors compared to patients with benign tumors (p = 0.035), whereas CatB levels did not differ within this histological subgroup. CF levels of CysC only differed between patients with malignant and benign tumors in the subgroup of serous tumors (p = 0.001).Table 2Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (n = 67) of benign, borderline and malignant tumors grouped by serous and mucinous subtypeSubtypeN (%)Cathepsin Bp-value*Cathepsin Lp-value*Cystatin Cp-value*Serous410.0310.1310.001 Serous cystadenoma29 (71)12 (1-269)a31 (9-121)572 (131-1,780)b Serous borderline tumor2 (5)14 (8-21)28 (18-38)1,449 (1,125-1,772) Serous cystadenocarcinoma10 (24)65 (3-269)a61 (8-163)1,443 (448-5,972)bMucinous350.3150.0170.136 Mucinous cystadenoma21 (60)16 (1-227)11 (1-95)c578 (39-9,984) Mucinous borderline tumor6 (17)32 (2-118)75 (8-166)697 (474-3,897) Mucinous cystadenocarcinoma8 (23)33 (5-269)31 (13-187)c959 (399-9,984)*Statistical significance according to ANOVAStudent's t testa, b, c of values normalized after Ln transformationap = 0.010 for serous cystadenoma compared to serous cystadenocarcinomabp = 0.001 for serous cystadenoma compared to serous cystadenocarcinomacp = 0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinomaFig. 1Box plots of the (a) cathepsin B and (b) cathepsin L, and (c) cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst fluid for patients with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors). Statistical significance above the subfigures are according to ANOVA (P < 0.05) with Tukey's HSD post hoc tests of values normalized after Ln transformation
###end p 32
###begin p 33
###xml 92 93 92 93 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (n = 67) of benign, borderline and malignant tumors grouped by serous and mucinous subtype
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
*Statistical significance according to ANOVA
###end p 34
###begin p 35
###xml 10 11 10 11 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 16 23 16 23 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a, b, c</sup>
Student's t testa, b, c of values normalized after Ln transformation
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1 2 1 2 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
ap = 0.010 for serous cystadenoma compared to serous cystadenocarcinoma
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1 2 1 2 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
bp = 0.001 for serous cystadenoma compared to serous cystadenocarcinoma
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1 2 1 2 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
cp = 0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinoma
###end p 38
###begin p 39
###xml 18 19 18 19 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 38 39 38 39 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 59 60 59 60 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 339 340 339 340 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Box plots of the (a) cathepsin B and (b) cathepsin L, and (c) cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst fluid for patients with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors). Statistical significance above the subfigures are according to ANOVA (P < 0.05) with Tukey's HSD post hoc tests of values normalized after Ln transformation
###end p 39
###begin title 40
Parameters of aggressiveness of the tumor
###end title 40
###begin p 41
###xml 6 7 6 7 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 293 294 293 294 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 515 522 515 522 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 624 625 624 625 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 522 707 522 707 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in malignant ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;26) according to clinicopathological parameters for aggressiveness of the tumor</p>
###xml 522 707 522 707 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in malignant ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;26) according to clinicopathological parameters for aggressiveness of the tumor</p></caption>
###xml 707 707 707 707 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 707 708 707 708 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 707 712 707 712 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>N</italic> (%)</th>
###xml 712 723 712 723 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cathepsin B</th>
###xml 723 724 723 724 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 723 730 723 730 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic>-value</th>
###xml 730 741 730 741 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cathepsin L</th>
###xml 741 742 741 742 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 741 748 741 748 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic>-value</th>
###xml 748 758 748 758 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cystatin C</th>
###xml 758 759 758 759 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 758 765 758 765 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic>-value</th>
###xml 707 765 707 765 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value</th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value</th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value</th></tr>
###xml 707 765 707 765 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value</th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value</th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value</th></tr></thead>
###xml 765 775 765 775 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">FIGO stage</td>
###xml 775 775 775 775 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 775 775 775 775 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 780 781 780 781 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 775 781 775 781 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.613<sup>a</sup></td>
###xml 781 781 781 781 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 786 787 786 787 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 781 787 781 787 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.984<sup>a</sup></td>
###xml 787 787 787 787 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 792 793 792 793 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 787 793 787 793 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.406<sup>a</sup></td>
###xml 765 793 765 793 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">FIGO stage</td><td align="left"/><td align="left"/><td char="." align="char">0.613<sup>a</sup></td><td align="left"/><td char="." align="char">0.984<sup>a</sup></td><td align="left"/><td char="." align="char">0.406<sup>a</sup></td></tr>
###xml 793 800 793 800 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Ia&#8211;IIa</td>
###xml 800 807 800 807 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">13 (50)</td>
###xml 807 817 807 817 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">48 (28&#8211;93)</td>
###xml 817 817 817 817 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 817 827 817 827 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">40 (29&#8211;78)</td>
###xml 827 827 827 827 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 827 844 827 844 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">1,040 (594&#8211;2,355)</td>
###xml 844 844 844 844 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 793 844 793 844 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Ia&#8211;IIa</td><td char="[" align="char">13 (50)</td><td char="(" align="char">48 (28&#8211;93)</td><td align="left"/><td char="(" align="char">40 (29&#8211;78)</td><td align="left"/><td char="[" align="char">1,040 (594&#8211;2,355)</td><td align="left"/></tr>
###xml 844 851 844 849 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#8805;IIb</td>
###xml 851 858 849 856 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">12 (46)</td>
###xml 858 869 856 867 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">72 (16&#8211;109)</td>
###xml 869 869 867 867 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 869 880 867 878 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">63 (18&#8211;125)</td>
###xml 880 880 878 878 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 880 899 878 897 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">1,233 (1,055&#8211;1,500)</td>
###xml 899 899 897 897 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 844 899 844 897 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#8805;IIb</td><td char="[" align="char">12 (46)</td><td char="(" align="char">72 (16&#8211;109)</td><td align="left"/><td char="(" align="char">63 (18&#8211;125)</td><td align="left"/><td char="[" align="char">1,233 (1,055&#8211;1,500)</td><td align="left"/></tr>
###xml 899 907 897 905 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Unknown</td>
###xml 907 912 905 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">1 (4)</td>
###xml 912 912 910 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 912 912 910 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 912 912 910 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 912 912 910 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 912 912 910 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char"/>
###xml 912 912 910 910 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 899 912 897 910 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Unknown</td><td char="[" align="char">1 (4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr>
###xml 912 923 910 921 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor grade</td>
###xml 923 923 921 921 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char"/>
###xml 923 923 921 921 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 928 929 926 927 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 923 929 921 927 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.554<sup>b</sup></td>
###xml 929 929 927 927 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 934 935 932 933 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 929 935 927 933 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.595<sup>b</sup></td>
###xml 935 935 933 933 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char"/>
###xml 940 941 938 939 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 935 941 933 939 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.535<sup>b</sup></td>
###xml 912 941 910 939 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tumor grade</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.554<sup>b</sup></td><td align="left"/><td char="." align="char">0.595<sup>b</sup></td><td char="[" align="char"/><td char="." align="char">0.535<sup>b</sup></td></tr>
###xml 941 943 939 941 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;1</td>
###xml 943 949 941 947 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">6 (23)</td>
###xml 949 960 947 958 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">38 (10&#8211;269)</td>
###xml 960 960 958 958 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 960 971 958 969 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">31 (14&#8211;187)</td>
###xml 971 971 969 969 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 971 986 969 984 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">959 (465&#8211;9,984)</td>
###xml 986 986 984 984 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 941 986 939 984 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;1</td><td char="[" align="char">6 (23)</td><td char="(" align="char">38 (10&#8211;269)</td><td align="left"/><td char="(" align="char">31 (14&#8211;187)</td><td align="left"/><td char="[" align="char">959 (465&#8211;9,984)</td><td align="left"/></tr>
###xml 986 988 984 986 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;2</td>
###xml 988 994 986 992 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">5 (19)</td>
###xml 994 1005 992 1003 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">71 (38&#8211;269)</td>
###xml 1005 1005 1003 1003 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1005 1016 1003 1014 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">62 (38&#8211;163)</td>
###xml 1016 1016 1014 1014 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1016 1033 1014 1031 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">1,076 (399&#8211;1,502)</td>
###xml 1033 1033 1031 1031 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 986 1033 984 1031 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;2</td><td char="[" align="char">5 (19)</td><td char="(" align="char">71 (38&#8211;269)</td><td align="left"/><td char="(" align="char">62 (38&#8211;163)</td><td align="left"/><td char="[" align="char">1,076 (399&#8211;1,502)</td><td align="left"/></tr>
###xml 1033 1035 1031 1033 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;3</td>
###xml 1035 1042 1033 1040 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">13 (50)</td>
###xml 1042 1051 1040 1049 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">64 (3&#8211;11)</td>
###xml 1051 1051 1049 1049 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1051 1061 1049 1059 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">64 (8&#8211;181)</td>
###xml 1061 1061 1059 1059 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1061 1078 1059 1076 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">1,324 (448&#8211;2,908)</td>
###xml 1078 1078 1076 1076 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1033 1078 1031 1076 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;3</td><td char="[" align="char">13 (50)</td><td char="(" align="char">64 (3&#8211;11)</td><td align="left"/><td char="(" align="char">64 (8&#8211;181)</td><td align="left"/><td char="[" align="char">1,324 (448&#8211;2,908)</td><td align="left"/></tr>
###xml 1078 1086 1076 1084 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Unknown</td>
###xml 1086 1091 1084 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">2 (8)</td>
###xml 1091 1091 1089 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1091 1091 1089 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1091 1091 1089 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1091 1091 1089 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1091 1091 1089 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char"/>
###xml 1091 1091 1089 1089 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1078 1091 1076 1089 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Unknown</td><td char="[" align="char">2 (8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr>
###xml 1091 1098 1089 1096 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ascites</td>
###xml 1098 1098 1096 1096 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char"/>
###xml 1098 1098 1096 1096 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1103 1104 1101 1102 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1098 1104 1096 1102 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.632<sup>a</sup></td>
###xml 1104 1104 1102 1102 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1109 1110 1107 1108 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1104 1110 1102 1108 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.379<sup>a</sup></td>
###xml 1110 1110 1108 1108 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char"/>
###xml 1115 1116 1113 1114 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1110 1116 1108 1114 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.569<sup>a</sup></td>
###xml 1091 1116 1089 1114 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Ascites</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.632<sup>a</sup></td><td align="left"/><td char="." align="char">0.379<sup>a</sup></td><td char="[" align="char"/><td char="." align="char">0.569<sup>a</sup></td></tr>
###xml 1116 1120 1114 1118 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Yes</td>
###xml 1120 1127 1118 1125 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">11 (42)</td>
###xml 1127 1137 1125 1135 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">76 (5&#8211;269)</td>
###xml 1137 1137 1135 1135 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1137 1148 1135 1146 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">64 (13&#8211;181)</td>
###xml 1148 1148 1146 1146 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1148 1167 1146 1165 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">1,330 (1,048&#8211;2,908)</td>
###xml 1167 1167 1165 1165 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1116 1167 1114 1165 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Yes</td><td char="[" align="char">11 (42)</td><td char="(" align="char">76 (5&#8211;269)</td><td align="left"/><td char="(" align="char">64 (13&#8211;181)</td><td align="left"/><td char="[" align="char">1,330 (1,048&#8211;2,908)</td><td align="left"/></tr>
###xml 1167 1170 1165 1168 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;No</td>
###xml 1170 1177 1168 1175 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">12 (46)</td>
###xml 1177 1188 1175 1186 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">55 (10&#8211;269)</td>
###xml 1188 1188 1186 1186 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1188 1199 1186 1197 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">48 (14&#8211;187)</td>
###xml 1199 1199 1197 1197 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1199 1214 1197 1212 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">970 (399&#8211;9,984)</td>
###xml 1214 1214 1212 1212 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1167 1214 1165 1212 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;No</td><td char="[" align="char">12 (46)</td><td char="(" align="char">55 (10&#8211;269)</td><td align="left"/><td char="(" align="char">48 (14&#8211;187)</td><td align="left"/><td char="[" align="char">970 (399&#8211;9,984)</td><td align="left"/></tr>
###xml 1214 1222 1212 1220 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Unknown</td>
###xml 1222 1228 1220 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" char="[" align="char">3 (12)</td>
###xml 1228 1228 1226 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1228 1228 1226 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1228 1228 1226 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1228 1228 1226 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1228 1228 1226 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1228 1228 1226 1226 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1214 1228 1212 1226 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Unknown</td><td char="[" align="char">3 (12)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 765 1228 765 1226 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">FIGO stage</td><td align="left"/><td align="left"/><td char="." align="char">0.613<sup>a</sup></td><td align="left"/><td char="." align="char">0.984<sup>a</sup></td><td align="left"/><td char="." align="char">0.406<sup>a</sup></td></tr><tr><td align="left">&#160;Ia&#8211;IIa</td><td char="[" align="char">13 (50)</td><td char="(" align="char">48 (28&#8211;93)</td><td align="left"/><td char="(" align="char">40 (29&#8211;78)</td><td align="left"/><td char="[" align="char">1,040 (594&#8211;2,355)</td><td align="left"/></tr><tr><td align="left">&#160;&#8805;IIb</td><td char="[" align="char">12 (46)</td><td char="(" align="char">72 (16&#8211;109)</td><td align="left"/><td char="(" align="char">63 (18&#8211;125)</td><td align="left"/><td char="[" align="char">1,233 (1,055&#8211;1,500)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">1 (4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Tumor grade</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.554<sup>b</sup></td><td align="left"/><td char="." align="char">0.595<sup>b</sup></td><td char="[" align="char"/><td char="." align="char">0.535<sup>b</sup></td></tr><tr><td align="left">&#160;1</td><td char="[" align="char">6 (23)</td><td char="(" align="char">38 (10&#8211;269)</td><td align="left"/><td char="(" align="char">31 (14&#8211;187)</td><td align="left"/><td char="[" align="char">959 (465&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;2</td><td char="[" align="char">5 (19)</td><td char="(" align="char">71 (38&#8211;269)</td><td align="left"/><td char="(" align="char">62 (38&#8211;163)</td><td align="left"/><td char="[" align="char">1,076 (399&#8211;1,502)</td><td align="left"/></tr><tr><td align="left">&#160;3</td><td char="[" align="char">13 (50)</td><td char="(" align="char">64 (3&#8211;11)</td><td align="left"/><td char="(" align="char">64 (8&#8211;181)</td><td align="left"/><td char="[" align="char">1,324 (448&#8211;2,908)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">2 (8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Ascites</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.632<sup>a</sup></td><td align="left"/><td char="." align="char">0.379<sup>a</sup></td><td char="[" align="char"/><td char="." align="char">0.569<sup>a</sup></td></tr><tr><td align="left">&#160;Yes</td><td char="[" align="char">11 (42)</td><td char="(" align="char">76 (5&#8211;269)</td><td align="left"/><td char="(" align="char">64 (13&#8211;181)</td><td align="left"/><td char="[" align="char">1,330 (1,048&#8211;2,908)</td><td align="left"/></tr><tr><td align="left">&#160;No</td><td char="[" align="char">12 (46)</td><td char="(" align="char">55 (10&#8211;269)</td><td align="left"/><td char="(" align="char">48 (14&#8211;187)</td><td align="left"/><td char="[" align="char">970 (399&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">3 (12)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody>
###xml 707 1228 707 1226 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value</th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value</th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">FIGO stage</td><td align="left"/><td align="left"/><td char="." align="char">0.613<sup>a</sup></td><td align="left"/><td char="." align="char">0.984<sup>a</sup></td><td align="left"/><td char="." align="char">0.406<sup>a</sup></td></tr><tr><td align="left">&#160;Ia&#8211;IIa</td><td char="[" align="char">13 (50)</td><td char="(" align="char">48 (28&#8211;93)</td><td align="left"/><td char="(" align="char">40 (29&#8211;78)</td><td align="left"/><td char="[" align="char">1,040 (594&#8211;2,355)</td><td align="left"/></tr><tr><td align="left">&#160;&#8805;IIb</td><td char="[" align="char">12 (46)</td><td char="(" align="char">72 (16&#8211;109)</td><td align="left"/><td char="(" align="char">63 (18&#8211;125)</td><td align="left"/><td char="[" align="char">1,233 (1,055&#8211;1,500)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">1 (4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Tumor grade</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.554<sup>b</sup></td><td align="left"/><td char="." align="char">0.595<sup>b</sup></td><td char="[" align="char"/><td char="." align="char">0.535<sup>b</sup></td></tr><tr><td align="left">&#160;1</td><td char="[" align="char">6 (23)</td><td char="(" align="char">38 (10&#8211;269)</td><td align="left"/><td char="(" align="char">31 (14&#8211;187)</td><td align="left"/><td char="[" align="char">959 (465&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;2</td><td char="[" align="char">5 (19)</td><td char="(" align="char">71 (38&#8211;269)</td><td align="left"/><td char="(" align="char">62 (38&#8211;163)</td><td align="left"/><td char="[" align="char">1,076 (399&#8211;1,502)</td><td align="left"/></tr><tr><td align="left">&#160;3</td><td char="[" align="char">13 (50)</td><td char="(" align="char">64 (3&#8211;11)</td><td align="left"/><td char="(" align="char">64 (8&#8211;181)</td><td align="left"/><td char="[" align="char">1,324 (448&#8211;2,908)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">2 (8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Ascites</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.632<sup>a</sup></td><td align="left"/><td char="." align="char">0.379<sup>a</sup></td><td char="[" align="char"/><td char="." align="char">0.569<sup>a</sup></td></tr><tr><td align="left">&#160;Yes</td><td char="[" align="char">11 (42)</td><td char="(" align="char">76 (5&#8211;269)</td><td align="left"/><td char="(" align="char">64 (13&#8211;181)</td><td align="left"/><td char="[" align="char">1,330 (1,048&#8211;2,908)</td><td align="left"/></tr><tr><td align="left">&#160;No</td><td char="[" align="char">12 (46)</td><td char="(" align="char">55 (10&#8211;269)</td><td align="left"/><td char="(" align="char">48 (14&#8211;187)</td><td align="left"/><td char="[" align="char">970 (399&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">3 (12)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table>
###xml 1228 1265 1226 1263 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="43">Statistical significance according to</p>
###xml 1265 1266 1263 1264 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1276 1277 1274 1275 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1265 1282 1263 1280 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="44"><sup>a</sup>Student&#8217;s <italic>t</italic> test</p>
###xml 1282 1283 1280 1281 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1282 1333 1280 1331 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="45"><sup>b</sup>ANOVA of values normalized after Ln transformation</p>
###xml 1228 1333 1226 1331 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="43">Statistical significance according to</p><p textid="44"><sup>a</sup>Student&#8217;s <italic>t</italic> test</p><p textid="45"><sup>b</sup>ANOVA of values normalized after Ln transformation</p></table-wrap-foot>
###xml 515 1333 515 1331 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="42">Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in malignant ovarian tumor cyst fluid (<italic>n</italic>&#160;=&#160;26) according to clinicopathological parameters for aggressiveness of the tumor</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value</th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value</th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">FIGO stage</td><td align="left"/><td align="left"/><td char="." align="char">0.613<sup>a</sup></td><td align="left"/><td char="." align="char">0.984<sup>a</sup></td><td align="left"/><td char="." align="char">0.406<sup>a</sup></td></tr><tr><td align="left">&#160;Ia&#8211;IIa</td><td char="[" align="char">13 (50)</td><td char="(" align="char">48 (28&#8211;93)</td><td align="left"/><td char="(" align="char">40 (29&#8211;78)</td><td align="left"/><td char="[" align="char">1,040 (594&#8211;2,355)</td><td align="left"/></tr><tr><td align="left">&#160;&#8805;IIb</td><td char="[" align="char">12 (46)</td><td char="(" align="char">72 (16&#8211;109)</td><td align="left"/><td char="(" align="char">63 (18&#8211;125)</td><td align="left"/><td char="[" align="char">1,233 (1,055&#8211;1,500)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">1 (4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Tumor grade</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.554<sup>b</sup></td><td align="left"/><td char="." align="char">0.595<sup>b</sup></td><td char="[" align="char"/><td char="." align="char">0.535<sup>b</sup></td></tr><tr><td align="left">&#160;1</td><td char="[" align="char">6 (23)</td><td char="(" align="char">38 (10&#8211;269)</td><td align="left"/><td char="(" align="char">31 (14&#8211;187)</td><td align="left"/><td char="[" align="char">959 (465&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;2</td><td char="[" align="char">5 (19)</td><td char="(" align="char">71 (38&#8211;269)</td><td align="left"/><td char="(" align="char">62 (38&#8211;163)</td><td align="left"/><td char="[" align="char">1,076 (399&#8211;1,502)</td><td align="left"/></tr><tr><td align="left">&#160;3</td><td char="[" align="char">13 (50)</td><td char="(" align="char">64 (3&#8211;11)</td><td align="left"/><td char="(" align="char">64 (8&#8211;181)</td><td align="left"/><td char="[" align="char">1,324 (448&#8211;2,908)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">2 (8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Ascites</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.632<sup>a</sup></td><td align="left"/><td char="." align="char">0.379<sup>a</sup></td><td char="[" align="char"/><td char="." align="char">0.569<sup>a</sup></td></tr><tr><td align="left">&#160;Yes</td><td char="[" align="char">11 (42)</td><td char="(" align="char">76 (5&#8211;269)</td><td align="left"/><td char="(" align="char">64 (13&#8211;181)</td><td align="left"/><td char="[" align="char">1,330 (1,048&#8211;2,908)</td><td align="left"/></tr><tr><td align="left">&#160;No</td><td char="[" align="char">12 (46)</td><td char="(" align="char">55 (10&#8211;269)</td><td align="left"/><td char="(" align="char">48 (14&#8211;187)</td><td align="left"/><td char="[" align="char">970 (399&#8211;9,984)</td><td align="left"/></tr><tr><td align="left">&#160;Unknown</td><td char="[" align="char">3 (12)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p textid="43">Statistical significance according to</p><p textid="44"><sup>a</sup>Student&#8217;s <italic>t</italic> test</p><p textid="45"><sup>b</sup>ANOVA of values normalized after Ln transformation</p></table-wrap-foot></table-wrap>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 198 201 <span type="species:ncbi:9685">Cat</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
Table 3 shows clinicopathological parameters of tumor aggressiveness and median (range) concentrations of CatB, CatL and CysC of the 26 patients with EOC. Since no differences in CF levels of CatB, Cat L and CysC were found between serous, mucinous and endometrioid cystadenocarcinomas (Table 1), data of patients with EOC were merged. When patients were grouped according to FIGO stage of disease, tumor grading and presence of ascites, no significant differences in CF levels of CatB, CatL and/or CysC were found.Table 3Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in malignant ovarian tumor cyst fluid (n = 26) according to clinicopathological parameters for aggressiveness of the tumorN (%)Cathepsin Bp-valueCathepsin Lp-valueCystatin Cp-valueFIGO stage0.613a0.984a0.406a Ia-IIa13 (50)48 (28-93)40 (29-78)1,040 (594-2,355) >/=IIb12 (46)72 (16-109)63 (18-125)1,233 (1,055-1,500) Unknown1 (4)Tumor grade0.554b0.595b0.535b 16 (23)38 (10-269)31 (14-187)959 (465-9,984) 25 (19)71 (38-269)62 (38-163)1,076 (399-1,502) 313 (50)64 (3-11)64 (8-181)1,324 (448-2,908) Unknown2 (8)Ascites0.632a0.379a0.569a Yes11 (42)76 (5-269)64 (13-181)1,330 (1,048-2,908) No12 (46)55 (10-269)48 (14-187)970 (399-9,984) Unknown3 (12)Statistical significance according toaStudent's t testbANOVA of values normalized after Ln transformation
###end p 41
###begin p 42
###xml 102 103 102 103 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in malignant ovarian tumor cyst fluid (n = 26) according to clinicopathological parameters for aggressiveness of the tumor
###end p 42
###begin p 43
Statistical significance according to
###end p 43
###begin p 44
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 11 12 11 12 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
aStudent's t test
###end p 44
###begin p 45
###xml 0 1 0 1 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bANOVA of values normalized after Ln transformation
###end p 45
###begin title 46
Correlation between cathepsins and cystatin C
###end title 46
###begin p 47
###xml 7 8 7 8 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 117 118 117 118 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 124 125 124 125 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 128 129 128 129 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 155 156 155 156 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 159 160 159 160 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 252 253 252 253 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 263 264 263 264 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 279 280 279 280 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 372 373 372 373 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 383 384 383 384 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 474 475 474 475 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 606 607 606 607 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 617 618 617 618 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 633 634 633 634 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 640 641 640 641 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 651 652 651 652 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 667 668 667 668 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 792 793 792 793 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 803 804 803 804 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 814 820 814 820 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 902 903 902 903 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 922 923 922 923 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 958 959 958 959 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 999 1000 999 1000 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1037 1038 1037 1038 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1072 1073 1072 1073 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1111 1112 1111 1112 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1155 1164 1155 1164 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Asterisks</italic>
###xml 1176 1190 1176 1190 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">open triangles</italic>
###xml 1203 1215 1203 1215 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">open circles</italic>
###xml 820 1222 820 1222 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Scatter plots of Ln-transformed values of cyst fluid cystatin C with cathepsin B (<bold>a</bold>) and cathepsin L (<bold>b</bold>) for patients with serous tumors (<italic>n</italic>&#160;=&#160;41) and cystatin C with cathepsin L (<bold>c</bold>) for patients with mucinous tumors (<italic>n</italic>&#160;=&#160;35). Statistical significance (<italic>p</italic>&#160;&lt;&#160;0.05) and correlation coefficient (<italic>R</italic>) according to Pearson&#8217;s correlation test. <italic>Asterisks</italic> malignant; <italic>open triangles</italic> borderline, <italic>open circles</italic> benign</p>
###xml 820 1222 820 1222 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Scatter plots of Ln-transformed values of cyst fluid cystatin C with cathepsin B (<bold>a</bold>) and cathepsin L (<bold>b</bold>) for patients with serous tumors (<italic>n</italic>&#160;=&#160;41) and cystatin C with cathepsin L (<bold>c</bold>) for patients with mucinous tumors (<italic>n</italic>&#160;=&#160;35). Statistical significance (<italic>p</italic>&#160;&lt;&#160;0.05) and correlation coefficient (<italic>R</italic>) according to Pearson&#8217;s correlation test. <italic>Asterisks</italic> malignant; <italic>open triangles</italic> borderline, <italic>open circles</italic> benign</p></caption>
###xml 1222 1222 1222 1222 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="432_2009_716_Fig2_HTML" id="MO2"/>
###xml 814 1222 814 1222 <fig xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="48">Scatter plots of Ln-transformed values of cyst fluid cystatin C with cathepsin B (<bold>a</bold>) and cathepsin L (<bold>b</bold>) for patients with serous tumors (<italic>n</italic>&#160;=&#160;41) and cystatin C with cathepsin L (<bold>c</bold>) for patients with mucinous tumors (<italic>n</italic>&#160;=&#160;35). Statistical significance (<italic>p</italic>&#160;&lt;&#160;0.05) and correlation coefficient (<italic>R</italic>) according to Pearson&#8217;s correlation test. <italic>Asterisks</italic> malignant; <italic>open triangles</italic> borderline, <italic>open circles</italic> benign</p></caption><graphic xlink:href="432_2009_716_Fig2_HTML" id="MO2"/></fig>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 929 937 <span type="species:ncbi:9606">patients</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
Figure 2 shows the scatter plots of the correlation between Cathepsins and Cystatin C for patients with serous (Fig. 2a and 2b; n = 41) and mucinous (Fig. 2c; n = 35) tumors. For serous tumors, CF levels of CysC and CatB were significantly correlated (p < 0.001, R = 0.652, Fig. 2a). The correlation between CF levels of CysC and CatB was highest for the malignant group (p < 0.001, R = 0.921). For mucinous tumors, CF levels of CysC and CatB did not show any relationship (p = 0.923, figure not shown). Correlations between CF levels of CysC and CatL were significant for both serous and mucinous tumors (p = 0.001, R = 0.491, Fig. 2b and p = 0.003; R = 0.481, Fig. 2c, respectively). For mucinous tumors, the correlation between CF levels of CysC and CatL was highest for the benign group (p < 0.001, R = 0.665).Fig. 2Scatter plots of Ln-transformed values of cyst fluid cystatin C with cathepsin B (a) and cathepsin L (b) for patients with serous tumors (n = 41) and cystatin C with cathepsin L (c) for patients with mucinous tumors (n = 35). Statistical significance (p < 0.05) and correlation coefficient (R) according to Pearson's correlation test. Asterisks malignant; open triangles borderline, open circles benign
###end p 47
###begin p 48
###xml 82 83 82 83 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 102 103 102 103 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 138 139 138 139 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 179 180 179 180 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 217 218 217 218 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 252 253 252 253 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 291 292 291 292 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 335 344 335 344 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Asterisks</italic>
###xml 356 370 356 370 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">open triangles</italic>
###xml 383 395 383 395 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">open circles</italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
Scatter plots of Ln-transformed values of cyst fluid cystatin C with cathepsin B (a) and cathepsin L (b) for patients with serous tumors (n = 41) and cystatin C with cathepsin L (c) for patients with mucinous tumors (n = 35). Statistical significance (p < 0.05) and correlation coefficient (R) according to Pearson's correlation test. Asterisks malignant; open triangles borderline, open circles benign
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
In this study, we examined ovarian CF levels of CatB, CatL and their extracellular inhibitor CysC. In benign tumors, remarkable differences in CF levels of cathepsins B and L were found between different histopathological subtypes. For serous tumors, the levels of CatB and CysC were significantly higher in the CF of patients with EOC compared to CF levels of patients with benign ovarian tumors. For mucinous tumors, the levels of CatL were significantly higher in the CF of patients with EOC compared to CF levels of patients with benign ovarian tumors. Furthermore, correlations between cyst fluid levels of CatB and CysC and between CatL and CysC were found. Finally, we investigated the relationship between the levels of CatB, CatL and CysC and parameters of tumor aggressiveness of EOC, but could not find significant differences between the subgroups of patients.
###end p 50
###begin p 51
###xml 171 175 171 175 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">1992</xref>
###xml 623 627 623 627 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1992</xref>
###xml 640 644 640 644 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1997</xref>
###xml 646 650 646 650 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1998</xref>
###xml 664 669 664 669 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1997a</xref>
###xml 671 672 671 672 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">b</xref>
###xml 689 693 689 693 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2001</xref>
###xml 707 711 707 711 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2001</xref>
###xml 725 729 725 729 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2001</xref>
###xml 749 753 749 753 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">1995</xref>
###xml 769 773 769 773 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2004</xref>
###xml 790 794 790 794 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2004</xref>
###xml 816 820 816 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2007</xref>
###xml 880 884 880 884 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">1997</xref>
###xml 1014 1018 1014 1018 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 1367 1371 1367 1371 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1995</xref>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 835 843 <span type="species:ncbi:9606">patients</span>
###xml 940 948 <span type="species:ncbi:9606">patients</span>
###xml 1091 1099 <span type="species:ncbi:9606">patients</span>
###xml 1223 1231 <span type="species:ncbi:9606">patients</span>
###xml 1322 1330 <span type="species:ncbi:9606">patients</span>
###xml 1444 1452 <span type="species:ncbi:9606">patients</span>
###xml 1490 1498 <span type="species:ncbi:9606">patients</span>
We are the first to describe that CF of ovarian tumors contains considerable amounts of CatB, CatL and CysC. In ascitic fluid of patients with ovarian cancer, Lah et al. (1992) found CatB and a large pool of free CysC. We showed that CF levels of these enzymes were higher in ovarian cancer patients compared to patients with benign ovarian tumors. Serum studies in patients with other types of cancer have demonstrated similar results, as levels of CatB, CatL and CysC were found to be higher in serum of patients with cancer compared to serum levels of patients with benign tumors or healthy controls (Gabrijelcic et al. 1992; Kos et al. 1997, 1998; Leto et al. 1997a, b; Strojan et al. 2001; Zore et al. 2001; Yano et al. 2001; Makarewicz et al. 1995; Miyake et al. 2004; Strojan et al. 2004; Mulaomerovic et al. 2007). In serum of patients with ovarian cancer, Warwas et al. (1997) found higher levels of CatB compared to the levels in patients with benign ovarian tumors. On the other hand, Nishikawa et al. (2004) could not observe a significant difference in serum CatB level between patients with benign ovarian tumors and ovarian cancer, although they did find a significantly higher level of CysC in the serum of patients with ovarian cancer. Only one study has been published investigating CatL in the serum of patients with ovarian tumors (Nishida et al. 1995). The authors found that the serum levels of CatL were elevated in 8/10 patients with ovarian cancer compared to 2/10 patients with benign ovarian tumors.
###end p 51
###begin p 52
###xml 148 152 148 152 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1993</xref>
###xml 319 323 319 323 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">1986</xref>
###xml 513 517 513 517 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2000</xref>
###xml 1255 1259 1255 1259 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2000</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 389 395 <span type="species:ncbi:9606">people</span>
###xml 601 609 <span type="species:ncbi:9606">patients</span>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
###xml 927 935 <span type="species:ncbi:9606">patients</span>
###xml 985 993 <span type="species:ncbi:9606">patients</span>
###xml 1075 1083 <span type="species:ncbi:9606">patients</span>
###xml 1231 1239 <span type="species:ncbi:9606">patients</span>
###xml 1271 1279 <span type="species:ncbi:9606">patients</span>
The mean age of patients with ovarian cancer is known to be significantly higher than that of patients with benign ovarian tumors (Merino and Jaffe 1993). This was also found in our study group. This might confound our results, as there is definite evidence that renal function decreases with age (Lindeman and Goldman 1986), which results in a reduced glomerular filtration rate in older people. CysC is known to be almost completely reabsorbed and catabolized in the proximal renal tubular cells (Stabuc et al. 2000). This might explain the higher serum levels of CysC that were reported earlier in patients with ovarian cancer compared to that in patients with benign ovarian tumors. However, we found no correlation in CF between age and CysC level within the subgroups of patients. In addition, it is unclear whether CysC levels in ovarian CF, in contrast to serum, are influenced by renal function. Finally, the group of patients with borderline tumors was of similar age as the patients with benign tumors, yet exhibited CatB, CatL and CysC levels similar to those of patients with ovarian cancer. The level of CysC might be changed also due to pathological renal failures, changing the glomerular filtration rate in cancer patients (Stabuc et al. 2000). However, patients included in this study, did not exhibit any impaired kidney function. Therefore, we believe that the results of CysC in this study have not been biased by age-related or pathological changes of kidney function.
###end p 52
###begin p 53
###xml 419 423 419 423 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2006</xref>
###xml 438 442 438 442 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 458 462 458 462 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2004</xref>
###xml 688 689 688 689 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1049 1053 1049 1053 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2000</xref>
###xml 1072 1076 1072 1076 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 1089 1093 1089 1093 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2000</xref>
###xml 540 548 <span type="species:ncbi:9606">patients</span>
###xml 649 657 <span type="species:ncbi:9606">patients</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
Remarkably, CatB and CysC CF levels were significantly higher in malignant serous tumors compared to benign serous tumors, whereas CatL CF levels were significantly higher in malignant mucinous tumors compared to benign mucinous tumors. This finding contributes to the theory that malignant serous and mucinous ovarian tumors are different diseases, with subtype-specific biomarker profiles (Heinzelmann-Schwarz et al. 2006; Kobel et al. 2008; Cloven et al. 2004). In addition, a significant correlation between CatB and CysC was found for patients with serous tumors. Moreover, the correlation of CatB and CysC was extremely strong in the group of patients with malignant serous tumors (R = 0.921), which might indicate that an increase of CF CatB in malignant tumors was balanced by a corresponding increase in CF CysC level. This finding could be interesting, as it was proposed in previous studies that a relative imbalance between CatB and CysC in patients with cancer might contribute to the invasion and metastasis of tumor cells (Kos et al. 2000; Nishikawa et al. 2004; Lah et al. 2000).
###end p 53
###begin p 54
###xml 852 856 852 856 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2001</xref>
###xml 864 868 864 868 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2004</xref>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
Although not significant, median CF levels of CatB and CatL were up to seven times higher in cystic endometriosis compared to the other histopathological subtypes, and levels were comparable to CF levels of ovarian cancer patients with unfavorable tumor characteristics. Noteworthy is that CysC did not differ between cystic endometriosis and other benign subtypes, which might suggest a different balance between CatB and CysC in endometriosis cysts compared to the other histological subtypes. This might be explained by the continuous breakdown of components of blood and stromal tissue in endometriosis without a malignant invasion or metastasis. However, it is now well established that endometriosis does have neoplastic potential and it has been associated with the development of endometrioid and clear-cell ovarian carcinoma (Feeley and Wells 2001; Wells 2004).
###end p 54
###begin p 55
###xml 127 131 127 131 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2007</xref>
###xml 148 152 148 152 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2007</xref>
###xml 610 614 610 614 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">1998</xref>
###xml 641 645 641 645 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1997</xref>
###xml 760 764 760 764 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1995</xref>
###xml 891 895 891 895 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2004</xref>
###xml 1345 1349 1345 1349 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1999</xref>
###xml 1351 1355 1351 1355 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2000</xref>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 1073 1081 <span type="species:ncbi:9606">patients</span>
###xml 1766 1774 <span type="species:ncbi:9606">patients</span>
###xml 1810 1818 <span type="species:ncbi:9606">patients</span>
Since ovarian cancer tissue is highly heterogeneous, multiple biopsies are necessary for a careful examination (Hogdall et al. 2007; Chauhan et al. 2007). This means that quantitation of cathepsins and cystatins in biological fluids of ovarian cancer patients has several clinical advantages over measurements in ovarian cancer tissue. We found that the levels of cathepsins and CysC in ovarian CF were much higher than that in serum of cancer patients, as reported in literature. More specifically, up to six times more CatB was found in CF than in the serum of patients with colorectal carcinoma (Kos et al. 1998) and melanoma (Kos et al. 1997), up to ten times more CatL was found in ovarian CF than in serum of patients with ovarian cancer (Nishida et al. 1995), and up to eight times more CysC was found in ovarian CF than in the serum of patients with ovarian cancer (Nishikawa et al. 2004). This might indicate that CatB, CatL as well as CysC are released from tumor cells into the CF to a greater extent than the release of these compounds into the serum of cancer patients. In this way, CF values may give a better reflection of local changes of the ovarian tumor than levels of cathepsins and its inhibitors in serum, which also might be affected by the systemic response on malignant disease and circadian variations (Cimerman et al. 1999, 2000). From a clinical perspective, preoperative aspiration of ovarian cyst fluid might cause iatrogenic metastasis of tumor cells, and ovarian cyst fluid can only be used as a source of biomarkers for predicting prognosis and response to therapy. We, therefore, investigated the relationship between clinicopathological parameters that correspond with tumor aggressiveness and the levels of CatB, CatL and CysC in patients with ovarian cancer. However, when patients were grouped according to FIGO stage of disease, tumor grading and presence of ascites, no significant differences in CF levels of CatB, CatL and/or CysC were found. This could be caused by the relatively small size of cyst fluid samples from malignant tumors in the present study.
###end p 55
###begin title 56
Conclusions
###end title 56
###begin p 57
###xml 157 160 <span type="species:ncbi:9685">Cat</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
CF levels of CatB, and its endogenous inhibitor CysC, were significantly higher in serous EOC compared to benign serous ovarian tumors, whereas CF levels of Cat L were significantly higher in mucinous EOC compared to benign mucinous ovarian tumors. The correlation between CatB and CysC was extremely strong for patients with serous EOC, which might indicate that an increase in CatB of these patients is balanced by a corresponding increase in CysC level. We feel that further studies with a larger series of samples from malignant tumors are needed to explore the possible prognostic value of cathepsins and CysC in ovarian CF.
###end p 57
###begin title 58
Open Access
###end title 58
###begin p 59
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
Molecular aspects of tumor cell invasion and metastasis
###end article-title 61
###begin article-title 62
Extracellular matrix components and proteolytic enzymes in uterine cervical carcinoma
###end article-title 62
###begin article-title 63
Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis
###end article-title 63
###begin article-title 64
Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy
###end article-title 64
###begin article-title 65
Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera
###end article-title 65
###begin article-title 66
Twenty-four hour variations of cystatin C and total cysteine proteinase inhibitory activity in sera from healthy subjects
###end article-title 66
###begin article-title 67
In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer
###end article-title 67
###begin article-title 68
Ovarian cancer
###end article-title 68
###begin article-title 69
Proteases as prognostic markers in cancer
###end article-title 69
###begin article-title 70
Precursor lesions of ovarian epithelial malignancy
###end article-title 70
###begin article-title 71
###xml 25 30 <span type="species:ncbi:9606">human</span>
Cathepsins B, H and L in human breast carcinoma
###end article-title 71
###begin article-title 72
A distinct molecular profile associated with mucinous epithelial ovarian cancer
###end article-title 72
###begin article-title 73
###xml 86 94 <span type="species:ncbi:9606">patients</span>
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study
###end article-title 73
###begin article-title 74
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
###end article-title 74
###begin article-title 75
Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer
###end article-title 75
###begin article-title 76
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients
###end article-title 76
###begin article-title 77
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer
###end article-title 77
###begin article-title 78
Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer
###end article-title 78
###begin article-title 79
Cystatins and stefins in ascites fluid from ovarian carcinoma
###end article-title 79
###begin article-title 80
###xml 81 86 <span type="species:ncbi:9606">human</span>
Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors
###end article-title 80
###begin article-title 81
Early events in the pathogenesis of epithelial ovarian cancer
###end article-title 81
###begin article-title 82
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications
###end article-title 82
###begin article-title 83
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis
###end article-title 83
###begin article-title 84
Anatomic and physiologic age changes in the kidney
###end article-title 84
###begin article-title 85
Metastatic potential correlates with enzymatic degradation of basement membrane collagen
###end article-title 85
###begin article-title 86
Cathepsin B in predicting the extent of the cervix carcinoma
###end article-title 86
###begin article-title 87
Age contrast in ovarian pathology
###end article-title 87
###begin article-title 88
###xml 46 49 <span type="species:ncbi:9606">men</span>
Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression
###end article-title 88
###begin article-title 89
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma
###end article-title 89
###begin article-title 90
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4
###end article-title 90
###begin article-title 91
The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer
###end article-title 91
###begin article-title 92
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics
###end article-title 92
###begin article-title 93
Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro
###end article-title 93
###begin article-title 94
Tissue cathepsins as tumor markers
###end article-title 94
###begin article-title 95
Pathology of ovarian cancer precursors
###end article-title 95
###begin article-title 96
Cathepsin B and its endogenous inhibitors: the role in tumor malignancy
###end article-title 96
###begin article-title 97
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy
###end article-title 97
###begin article-title 98
Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck
###end article-title 98
###begin article-title 99
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Serum cystatin C in patients with head and neck carcinoma
###end article-title 99
###begin article-title 100
Lysosomal cysteine proteases: more than scavengers
###end article-title 100
###begin article-title 101
Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma
###end article-title 101
###begin article-title 102
Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation
###end article-title 102
###begin article-title 103
###xml 44 49 <span type="species:ncbi:9606">human</span>
Expression of cathepsin B and cystatin C in human breast cancer
###end article-title 103
###begin article-title 104
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer
###end article-title 104

